AnaptysBio, Inc. (NASDAQ: ANAB) Stock Competitors & Peer Comparison
See ANAB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ANAB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ANAB | $48.28 | -0.74% | 1.4B | -44.70 | -$1.08 | N/A |
| VRTX | $558.88 | +3.50% | 141.7B | 29.37 | $19.03 | N/A |
| REGN | $927.89 | +13.33% | 95.5B | 20.32 | $45.63 | +0.40% |
| MRNA | $221.72 | -0.47% | 88.5B | -27.19 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $892.87 | -0.55% | 54.8B | 32.19 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.81 | +1.82% | 41.8B | -1.12 | -$8.82 | N/A |
| RVMD | $191.31 | +0.55% | 41B | -21.69 | -$8.82 | N/A |
| ONC | $370.33 | -0.33% | 39.6B | 65.20 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ANAB vs VRTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, VRTX has a market cap of 141.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while VRTX trades at $558.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas VRTX's P/E ratio is 29.37. In terms of profitability, ANAB's ROE is +25.15%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ANAB is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ANAB vs REGN Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, REGN has a market cap of 95.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while REGN trades at $927.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas REGN's P/E ratio is 20.32. In terms of profitability, ANAB's ROE is +25.15%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ANAB is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
ANAB vs MRNA Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, MRNA has a market cap of 88.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while MRNA trades at $221.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas MRNA's P/E ratio is -27.19. In terms of profitability, ANAB's ROE is +25.15%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ANAB is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
ANAB vs VRNA Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ANAB's ROE is +25.15%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ANAB is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ANAB vs ARGX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ARGX has a market cap of 54.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ARGX trades at $892.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ARGX's P/E ratio is 32.19. In terms of profitability, ANAB's ROE is +25.15%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, ANAB is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ANAB vs SGEN Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ANAB's ROE is +25.15%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ANAB is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ANAB vs RVMDW Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RVMDW trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, ANAB's ROE is +25.15%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ANAB is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ANAB vs RVMD Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RVMD trades at $191.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RVMD's P/E ratio is -21.69. In terms of profitability, ANAB's ROE is +25.15%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ANAB is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
ANAB vs ONC Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ONC has a market cap of 39.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ONC trades at $370.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ONC's P/E ratio is 65.20. In terms of profitability, ANAB's ROE is +25.15%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ANAB is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check ONC's competition here
Genmab A/S (NASDAQ: GMAB)
ANAB vs GMAB Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, GMAB has a market cap of 34.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while GMAB trades at $57.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas GMAB's P/E ratio is 42.57. In terms of profitability, ANAB's ROE is +25.15%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ANAB is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ANAB vs ROIV Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ROIV has a market cap of 26.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ROIV trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ROIV's P/E ratio is -35.10. In terms of profitability, ANAB's ROE is +25.15%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ANAB is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ANAB vs UTHR Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, UTHR has a market cap of 25.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while UTHR trades at $598.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas UTHR's P/E ratio is 21.42. In terms of profitability, ANAB's ROE is +25.15%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ANAB is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check UTHR's competition here
Insmed Incorporated (NASDAQ: INSM)
ANAB vs INSM Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, INSM has a market cap of 24.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while INSM trades at $112.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas INSM's P/E ratio is -27.40. In terms of profitability, ANAB's ROE is +25.15%, compared to INSM's ROE of -0.83%. Regarding short-term risk, ANAB is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
ANAB vs INCY Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while INCY trades at $120.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas INCY's P/E ratio is 16.18. In terms of profitability, ANAB's ROE is +25.15%, compared to INCY's ROE of +0.07%. Regarding short-term risk, ANAB is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ANAB vs ALNY Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ALNY has a market cap of 22B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ALNY trades at $165.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ALNY's P/E ratio is 29.68. In terms of profitability, ANAB's ROE is +25.15%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, ANAB is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
ANAB vs BNTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, BNTX has a market cap of 21.9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while BNTX trades at $88.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas BNTX's P/E ratio is -11.43. In terms of profitability, ANAB's ROE is +25.15%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ANAB is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ANAB vs BGNE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ANAB's ROE is +25.15%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ANAB is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ANAB vs DNA-WT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ANAB's ROE is +25.15%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ANAB is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ANAB vs EXEL Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, EXEL has a market cap of 17.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while EXEL trades at $69.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas EXEL's P/E ratio is 19.83. In terms of profitability, ANAB's ROE is +25.15%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, ANAB is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ANAB vs ASND Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ASND trades at $251.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ASND's P/E ratio is -103.74. In terms of profitability, ANAB's ROE is +25.15%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ANAB is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ASND's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ANAB vs HALO Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, HALO has a market cap of 14.9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while HALO trades at $130.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas HALO's P/E ratio is 24.43. In terms of profitability, ANAB's ROE is +25.15%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ANAB is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check HALO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ANAB vs NBIX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, NBIX has a market cap of 14.9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while NBIX trades at $146.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas NBIX's P/E ratio is 21.11. In terms of profitability, ANAB's ROE is +25.15%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ANAB is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check NBIX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ANAB vs BBIO Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while BBIO trades at $74.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas BBIO's P/E ratio is -20.04. In terms of profitability, ANAB's ROE is +25.15%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, ANAB is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ANAB vs JAZZ Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, JAZZ has a market cap of 14B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while JAZZ trades at $215.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas JAZZ's P/E ratio is 8.05. In terms of profitability, ANAB's ROE is +25.15%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ANAB is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check JAZZ's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ANAB vs SMMT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, SMMT has a market cap of 12.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while SMMT trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas SMMT's P/E ratio is -14.31. In terms of profitability, ANAB's ROE is +25.15%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ANAB is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ANAB vs KRTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ANAB's ROE is +25.15%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ANAB is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ANAB vs TECH Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while TECH trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas TECH's P/E ratio is 37.46. In terms of profitability, ANAB's ROE is +25.15%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ANAB is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check TECH's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ANAB vs BMRN Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while BMRN trades at $58.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas BMRN's P/E ratio is 28.14. In terms of profitability, ANAB's ROE is +25.15%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ANAB is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ANAB vs RNAM Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ANAB's ROE is +25.15%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ANAB is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ANAB vs KYMR Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, KYMR has a market cap of 10.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while KYMR trades at $126.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas KYMR's P/E ratio is -39.58. In terms of profitability, ANAB's ROE is +25.15%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ANAB is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check KYMR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ANAB vs TWST Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, TWST has a market cap of 10.1B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while TWST trades at $152.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas TWST's P/E ratio is -68.83. In terms of profitability, ANAB's ROE is +25.15%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ANAB is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ANAB vs MDGL Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while MDGL trades at $430.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas MDGL's P/E ratio is -33.62. In terms of profitability, ANAB's ROE is +25.15%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ANAB is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check MDGL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ANAB vs KRYS Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while KRYS trades at $332.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas KRYS's P/E ratio is 41.60. In terms of profitability, ANAB's ROE is +25.15%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ANAB is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check KRYS's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ANAB vs PCVX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, PCVX has a market cap of 9.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while PCVX trades at $62.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas PCVX's P/E ratio is -8.13. In terms of profitability, ANAB's ROE is +25.15%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ANAB is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check PCVX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ANAB vs CAI Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CAI has a market cap of 9.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CAI trades at $34.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CAI's P/E ratio is 96.46. In terms of profitability, ANAB's ROE is +25.15%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ANAB is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check CAI's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ANAB vs RXDX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ANAB's ROE is +25.15%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ANAB is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ANAB vs PTGX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while PTGX trades at $144.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas PTGX's P/E ratio is 140.75. In terms of profitability, ANAB's ROE is +25.15%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ANAB is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check PTGX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ANAB vs TGTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, TGTX has a market cap of 9.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while TGTX trades at $61.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas TGTX's P/E ratio is 22.17. In terms of profitability, ANAB's ROE is +25.15%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ANAB is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check TGTX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ANAB vs NUVL Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ANAB's ROE is +25.15%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ANAB is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check NUVL's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ANAB vs TXG Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, TXG has a market cap of 9.1B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while TXG trades at $70.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas TXG's P/E ratio is -118.82. In terms of profitability, ANAB's ROE is +25.15%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ANAB is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check TXG's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ANAB vs CRNX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ANAB's ROE is +25.15%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ANAB is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check CRNX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ANAB vs SYRE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, SYRE has a market cap of 8.9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while SYRE trades at $96.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas SYRE's P/E ratio is -49.54. In terms of profitability, ANAB's ROE is +25.15%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ANAB is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check SYRE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ANAB vs IBRX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while IBRX trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas IBRX's P/E ratio is -8.54. In terms of profitability, ANAB's ROE is +25.15%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ANAB is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check IBRX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ANAB vs CYTK Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CYTK has a market cap of 8.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CYTK trades at $62.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CYTK's P/E ratio is -8.72. In terms of profitability, ANAB's ROE is +25.15%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ANAB is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check CYTK's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ANAB vs IMGN Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ANAB's ROE is +25.15%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ANAB is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check IMGN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ANAB vs ARWR Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ARWR trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ARWR's P/E ratio is -26.61. In terms of profitability, ANAB's ROE is +25.15%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ANAB is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ARWR's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ANAB vs APGE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas APGE's P/E ratio is -31.19. In terms of profitability, ANAB's ROE is +25.15%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ANAB is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ANAB vs BPMC Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ANAB's ROE is +25.15%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ANAB is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ANAB vs CERE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CERE's P/E ratio is -16.47. In terms of profitability, ANAB's ROE is +25.15%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ANAB is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check CERE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ANAB vs PRAX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, PRAX has a market cap of 8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while PRAX trades at $285.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas PRAX's P/E ratio is -22.10. In terms of profitability, ANAB's ROE is +25.15%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ANAB is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check PRAX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ANAB vs AXSM Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, AXSM has a market cap of 7.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while AXSM trades at $144.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas AXSM's P/E ratio is -37.77. In terms of profitability, ANAB's ROE is +25.15%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ANAB is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check AXSM's competition here
Abivax S.A. (NASDAQ: ABVX)
ANAB vs ABVX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ABVX has a market cap of 7.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ABVX trades at $86.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ABVX's P/E ratio is -14.19. In terms of profitability, ANAB's ROE is +25.15%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ANAB is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ABVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ANAB vs MTSR Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ANAB's ROE is +25.15%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ANAB is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ANAB vs IONS Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while IONS trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas IONS's P/E ratio is -13.31. In terms of profitability, ANAB's ROE is +25.15%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ANAB is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check IONS's competition here
Merus N.V. (NASDAQ: MRUS)
ANAB vs MRUS Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ANAB's ROE is +25.15%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ANAB is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ANAB vs ACLX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ANAB's ROE is +25.15%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, ANAB is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ANAB vs RETA Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RETA's P/E ratio is -66.29. In terms of profitability, ANAB's ROE is +25.15%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ANAB is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check RETA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ANAB vs LGND Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, LGND has a market cap of 6.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while LGND trades at $322.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas LGND's P/E ratio is 35.42. In terms of profitability, ANAB's ROE is +25.15%, compared to LGND's ROE of +0.05%. Regarding short-term risk, ANAB is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check LGND's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ANAB vs ORKA Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ORKA has a market cap of 6.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ORKA trades at $96.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ORKA's P/E ratio is -49.92. In terms of profitability, ANAB's ROE is +25.15%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ANAB is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ORKA's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ANAB vs RYTM Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RYTM trades at $92.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RYTM's P/E ratio is -29.78. In terms of profitability, ANAB's ROE is +25.15%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ANAB is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check RYTM's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ANAB vs CNTA Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ANAB's ROE is +25.15%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ANAB is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
ANAB vs KOD Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while KOD trades at $99.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas KOD's P/E ratio is -23.78. In terms of profitability, ANAB's ROE is +25.15%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ANAB is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ANAB vs BLTE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while BLTE trades at $154.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas BLTE's P/E ratio is -82.96. In terms of profitability, ANAB's ROE is +25.15%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ANAB is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check BLTE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ANAB vs TERN Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas TERN's P/E ratio is -51.41. In terms of profitability, ANAB's ROE is +25.15%, compared to TERN's ROE of -0.14%. Regarding short-term risk, ANAB is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check TERN's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ANAB vs IMVT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, IMVT has a market cap of 6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while IMVT trades at $29.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas IMVT's P/E ratio is -10.34. In terms of profitability, ANAB's ROE is +25.15%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ANAB is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check IMVT's competition here
Veradermics, Incorporated (NYSE: MANE)
ANAB vs MANE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while MANE trades at $139.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas MANE's P/E ratio is -44.48. In terms of profitability, ANAB's ROE is +25.15%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ANAB is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check MANE's competition here
CG Oncology Inc. (NASDAQ: CGON)
ANAB vs CGON Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CGON trades at $64.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CGON's P/E ratio is -23.98. In terms of profitability, ANAB's ROE is +25.15%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ANAB is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check CGON's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ANAB vs CDTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ANAB's ROE is +25.15%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ANAB is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ANAB vs ABCM Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ANAB's ROE is +25.15%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ANAB is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ANAB vs ISEE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ANAB's ROE is +25.15%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ANAB is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check ISEE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ANAB vs MIRM Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while MIRM trades at $85.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas MIRM's P/E ratio is -5.83. In terms of profitability, ANAB's ROE is +25.15%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ANAB is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ANAB vs COGT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while COGT trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas COGT's P/E ratio is -14.69. In terms of profitability, ANAB's ROE is +25.15%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ANAB is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check COGT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ANAB vs SRRK Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while SRRK trades at $43.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas SRRK's P/E ratio is -12.72. In terms of profitability, ANAB's ROE is +25.15%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ANAB is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ANAB vs APLS Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas APLS's P/E ratio is 38.35. In terms of profitability, ANAB's ROE is +25.15%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ANAB is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
ANAB vs ERAS Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ERAS trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ERAS's P/E ratio is -15.41. In terms of profitability, ANAB's ROE is +25.15%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ANAB is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ERAS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ANAB vs PTCT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, PTCT has a market cap of 5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while PTCT trades at $59.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas PTCT's P/E ratio is -25.73. In terms of profitability, ANAB's ROE is +25.15%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, ANAB is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ANAB vs CRSP Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CRSP trades at $51.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CRSP's P/E ratio is -10.80. In terms of profitability, ANAB's ROE is +25.15%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ANAB is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ANAB vs DFTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while DFTX trades at $36.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas DFTX's P/E ratio is N/A. In terms of profitability, ANAB's ROE is +25.15%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ANAB is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ANAB vs TVTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while TVTX trades at $50.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas TVTX's P/E ratio is -111.98. In terms of profitability, ANAB's ROE is +25.15%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ANAB is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ANAB vs DNTH Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while DNTH trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas DNTH's P/E ratio is -19.87. In terms of profitability, ANAB's ROE is +25.15%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ANAB is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check DNTH's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ANAB vs FOLD Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ANAB's ROE is +25.15%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ANAB is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ANAB vs AKRO Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ANAB's ROE is +25.15%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, ANAB is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ANAB vs ALPN Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ANAB's ROE is +25.15%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ANAB is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check ALPN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ANAB vs ADPT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ADPT trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ADPT's P/E ratio is -64.93. In terms of profitability, ANAB's ROE is +25.15%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ANAB is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ADPT's competition here
Opthea Limited (NASDAQ: OPT)
ANAB vs OPT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas OPT's P/E ratio is -1.52. In terms of profitability, ANAB's ROE is +25.15%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ANAB is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ANAB vs PRTC Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ANAB's ROE is +25.15%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ANAB is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check PRTC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ANAB vs EWTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while EWTX trades at $38.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas EWTX's P/E ratio is -21.03. In terms of profitability, ANAB's ROE is +25.15%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ANAB is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ANAB vs MRTX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ANAB's ROE is +25.15%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ANAB is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check MRTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
ANAB vs ARQT Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ARQT has a market cap of 4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ARQT trades at $32.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ARQT's P/E ratio is 152.62. In terms of profitability, ANAB's ROE is +25.15%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, ANAB is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ARQT's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ANAB vs RLAY Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RLAY trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RLAY's P/E ratio is -11.68. In terms of profitability, ANAB's ROE is +25.15%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ANAB is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check RLAY's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ANAB vs LEGN Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while LEGN trades at $21.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas LEGN's P/E ratio is -31.79. In terms of profitability, ANAB's ROE is +25.15%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ANAB is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check LEGN's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ANAB vs ABCL Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, ABCL has a market cap of 4B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while ABCL trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas ABCL's P/E ratio is -22.71. In terms of profitability, ANAB's ROE is +25.15%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ANAB is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ANAB vs CPRX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ANAB's ROE is +25.15%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ANAB is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check CPRX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ANAB vs IOVA Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while IOVA trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas IOVA's P/E ratio is -11.60. In terms of profitability, ANAB's ROE is +25.15%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ANAB is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check IOVA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ANAB vs TNGX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while TNGX trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas TNGX's P/E ratio is -27.37. In terms of profitability, ANAB's ROE is +25.15%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ANAB is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check TNGX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ANAB vs RYZB Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ANAB's ROE is +25.15%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ANAB is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ANAB vs CBAY Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ANAB's ROE is +25.15%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ANAB is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ANAB.Check CBAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ANAB vs XENE Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, XENE has a market cap of 3.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while XENE trades at $37.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas XENE's P/E ratio is -7.96. In terms of profitability, ANAB's ROE is +25.15%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ANAB is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ANAB vs AMLX Comparison November 2026
AnaptysBio, Inc. (NASDAQ: ANAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANAB stands at 1.4B. In comparison, AMLX has a market cap of 3.6B. Regarding current trading prices, ANAB is priced at $48.28 on the NASDAQ, while AMLX trades at $28.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANAB currently has a P/E ratio of -44.70, whereas AMLX's P/E ratio is -19.24. In terms of profitability, ANAB's ROE is +25.15%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, ANAB is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for ANAB.Check AMLX's competition here